Cancer epigenetics: From disruption of differentiation programs to the emergence of cancer stem cells

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 75, Issue , 2010, Pages 251-258

  Scaffidi, P ^a   Misteli, T ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 5; HISTONE H3; HISTONE H3 LYSINE 27; HISTONE H3 LYSINE 4; HISTONE METHYLTRANSFERASE; KRUPPEL LIKE FACTOR 4; MICRORNA; MIXED LINEAGE LEUKEMIA PROTEIN; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN P53; SIRTUIN; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER STEM CELL; CARCINOGENESIS; CELL CYCLE; CELL DIFFERENTIATION; CELL RENEWAL; CELL SURVIVAL; CELL TRANSFORMATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; CHROMOSOME REARRANGEMENT; COLON CANCER; CPG ISLAND; DNA METHYLATION; EMBRYONIC STEM CELL; ENZYME ACTIVITY; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENOMIC INSTABILITY; HISTONE MODIFICATION; HUMAN; LEUKEMIA; LOSS OF FUNCTION MUTATION; LYMPHOMA; MALIGNANT TRANSFORMATION; MEMORY CELL; MIXED LINEAGE LEUKEMIA; MYELOID LEUKEMIA; NEOPLASM; NONHUMAN; NUCLEAR REPROGRAMMING; ONCOGENE; ONCOGENE C MYC; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROSTATE CANCER; SOLID TUMOR; SOMATIC CELL; TUMOR SUPPRESSOR GENE; INDUCED PLURIPOTENT STEM CELL; MALIGNANT NEOPLASM;

ANIMALS; CELL DIFFERENTIATION; EPIGENESIS, GENETIC; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MODELS, BIOLOGICAL; NEOPLASMS; NEOPLASTIC STEM CELLS; NUCLEAR REPROGRAMMING;

EID: 80052404953     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2010.75.007     Document Type: Article

References (78)

1. Andres AC, van der Valk MA, Schonenberger CA, Fluckiger F, LeMeur M, Gerlinger P, Groner B. 1988. Ha-ras and c-myc oncogene expression interferes with morphological and functional differentiation of mammary epithelial cells in single and double transgenic mice. Genes Dev 2: 1486-1495.
2. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, Danenberg E, Clarke AR, Sansom OJ, Clevers H. 2009. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457: 608-611.
3. Baylin SB, Ohm JE. 2006. Epigenetic gene silencing in cancer: A mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6: 107-116.
4. Benetti R, Gonzalo S, Jaco I, Munoz P, Gonzalez S, Schoeftner S, Murchison E, Andl T, Chen T, Klatt P, et al. 2008. A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases. Nat Struct Mol Biol 15: 268-279.
5. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA. 2008. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499-507.
6. Bird AP, Wolffe AP. 1999. Methylation-induced repression: Belts, braces, and chromatin. Cell 99: 451-454.
7. Botrugno OA, Santoro F, Minucci S. 2009. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett 280: 134-144.
8. Breiling A, Sessa L, Orlando V. 2007. Biology of Polycomb and Trithorax group proteins. Int Rev Cytol 258: 83-136.
9. Brock MV, Herman JG, Baylin SB. 2007. Cancer as a manifestation of aberrant chromatin structure. Cancer J 13: 3-8.
10. Calin GA, Croce CM. 2006. MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene 25: 6202-6210.
11. Cartwright P, McLean C, Sheppard A, Rivett D, Jones K, Dalton S. 2005. LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism. Development 132: 885-896.
12. Chen Y, Shi L, Zhang L, Li R, Liang J, Yu W, Sun L, Yang X, Wang Y, Zhang Y, et al. 2008. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 283: 17969-17978.
13. Chi P, Allis CD, Wang GG. 2010. Covalent histone modifications: Miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 10: 457-469.
14. Cicalese A, Bonizzi G, Pasi CE, Faretta M, Ronzoni S, Giulini B, Brisken C, Minucci S, Di Fiore PP, Pelicci PG. 2009. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 138: 1083-1095.
15. Clark SJ, Melki J. 2002. DNA methylation and gene silencing in cancer: Which is the guilty party? Oncogene 21: 5380-5387.
16. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. 2006. Cancer stem cells: Perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66: 9339-9344.
17. Davis PK, Brackmann RK. 2003. Chromatin remodeling and cancer. Cancer Biol Ther 2: 22-29.
18. Dialynas GK, Vitalini MW, Wallrath LL. 2008. Linking Heterochromatin Protein 1 (HP1) to cancer progression. Mutat Res 647: 13-20.
19. Doi A, Park IH, Wen B, Murakami P, Aryee MJ, Irizarry R, Herb B, Ladd-Acosta C, Rho J, Loewer S, et al. 2009. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 41: 1350-1353.
20. Ellis L, Atadja PW, Johnstone RW. 2009. Epigenetics in cancer: Targeting chromatin modifications. Mol Cancer Ther 8: 1409-1420.
21. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, et al. 2007. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci 104: 15805-15810.
22. Feinberg AP, Gehrke CW, Kuo KC, Ehrlich M. 1988. Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res 48: 1159-1161.
23. Feinberg AP, Ohlsson R, Henikoff S. 2006. The epigenetic progenitor origin of human cancer. Nat Rev Genet 7: 21-33.
24. Fialkow PJ, Denman AM, Jacobson RJ, Lowenthal MN. 1978. Chronic myelocytic leukemia. Origin of some lymphocytes from leukemic stem cells. J Clin Invest 62: 815-823.
25. Foster KW, Ren S, Louro ID, Lobo-Ruppert SM, McKie-Bell P, Grizzle W, Hayes MR, Broker TR, Chow LT, Ruppert JM. 1999. Oncogene expression cloning by retroviral transduction of adenovirus E1A-immortalized rat kidney RK3E cells: Transformation of a host with epithelial features by c-MYC and the zinc finger protein GKLF. Cell Growth Differ 10: 423-434.
26. Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin SF, Daigo Y, Russell P, Wilson A, Sowter HM, et al. 2000. Mutations truncating the EP300 acetylase in human cancers. Nat Genet 24: 300-303.
27. Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP. 1985. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 228: 187-190.
28. Gorrini C, Squatrito M, Luise C, Syed N, Perna D, Wark L, Martinato F, Sardella D, Verrecchia A, Bennett S, et al. 2007. Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature 448: 1063-1067.
29. Guil S, Esteller M. 2009. DNA methylomes, histone codes and miRNAs: Tying it all together. Int J Biochem Cell Biol 41: 87-95.
30. Guo M, House MG, Hooker C, Han Y, Heath E, Gabrielson E, Yang SC, Baylin SB, Herman JG, Brock MV. 2004. Promoter hypermethylation of resected bronchial margins: A field defect of changes? Clin Cancer Res 10: 5131-5136.
31. Heppner GH. 1984. Tumor heterogeneity. Cancer Res 44: 2259-2265.
32. Herman JG, Baylin SB. 2003. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054.
33. Hochedlinger K, Yamada Y, Beard C, Jaenisch R. 2005. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 121: 465-477.
34. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K, Yamanaka S. 2009. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460: 1132-1135.
35. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, Cui H, Gabo K, Rongione M, Webster M, et al. 2009. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 41: 178-186.
36. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, et al. 2004. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351: 657-667.
37. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP. 1998. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19: 187-191.
38. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, Wahl GM, Belmonte JC. 2009. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 460: 1140-1144.
39. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, Levine JE, Wang J, Hahn WC, Gilliland DG, et al. 2006. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442: 818-822.
40. Lang B, Liu HL, Liu R, Feng GD, Jiao XY, Ju G. 2004. Astrocytes in injured adult rat spinal cord may acquire the potential of neural stem cells. Neuroscience 128: 775-783.
41. Lewis BP, Burge CB, Bartel DP. 2005. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20.
42. Li H, Collado M, Villasante A, Strati K, Ortega S, Canamero M, Blasco MA, Serrano M. 2009. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 460: 1136-1139.
43. Liu T, Tee AE, Porro A, Smith SA, Dwarte T, Liu PY, Iraci N, Sekyere E, Haber M, Norris MD, et al. 2007. Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. Proc Natl Acad Sci 104: 18682-18687.
44. Liu A, Cheng L, Du J, Peng Y, Allan RW, Wei L, Li J, Cao D. 2010. Diagnostic utility of novel stem cell markers SALL4, OCT4, NANOG, SOX2, UTF1, and TCL1 in primary mediastinal germ cell tumors. Am J Surg Pathol 34: 697-706.
45. Marion RM, Strati K, Li H, Murga M, Blanco R, Ortega S, Fernandez-Capetillo O, Serrano M, Blasco MA. 2009. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 460: 1149-1153.
46. Mikkelsen TS, Hanna J, Zhang X, Ku M, Wernig M, Schorderet P, Bernstein BE, Jaenisch R, Lander ES, Meissner A. 2008. Dissecting direct reprogramming through integrative genomic analysis. Nature 454: 49-55.
47. Nishigaki M, Aoyagi K, Danjoh I, Fukaya M, Yanagihara K, Sakamoto H, Yoshida T, Sasaki H. 2005. Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays. Cancer Res 65: 2115-2124.
48. Oshimo Y, Nakayama H, Ito R, Kitadai Y, Yoshida K, Chayama K, Yasui W. 2003. Promoter methylation of cyclin D2 gene in gastric carcinoma. Int J Oncol 23: 1663-1670.
49. Owens GK, Kumar MS, Wamhoff BR. 2004. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 84: 767-801.
50. Pandya AY, Talley LI, Frost AR, Fitzgerald TJ, Trivedi V, Chakravarthy M, Chhieng DC, Grizzle WE, Engler JA, Krontiras H, et al. 2004. Nuclear localization of KLF4 is associated with an aggressive phenotype in early-stage breast cancer. Clin Cancer Res 10: 2709-2719.
51. Pardal R, Clarke MF, Morrison SJ. 2003. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3: 895-902.
52. Passegué E, Wagner EF, Weissman IL. 2004. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell 119: 431-443.
53. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, Bernard L, Viale G, Pelicci PG, Di Fiore PP. 2010. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140: 62-73.
54. Peng S, Maihle NJ, Huang Y. 2010. Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Oncogene 29: 2153-2159.
55. Perez-Caro M, Cobaleda C, Gonzalez-Herrero I, Vicente-Duenas C, Bermejo-Rodriguez C, Sanchez-Beato M, Orfao A, Pintado B, Flores T, Sanchez-Martin M, et al. 2009. Cancer induction by restriction of oncogene expression to the stem cell compartment. EMBO J 28: 8-20.
56. Rapp UR, Ceteci F, Schreck R. 2008. Oncogene-induced plasticity and cancer stem cells. Cell Cycle 7: 45-51.
57. Reya T, Morrison SJ, Clarke MF, Weissman IL. 2001. Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
58. Sato N, Maitra A, Fukushima N, van Heek NT, Matsubayashi H, Iacobuzio-Donahue CA, Rosty C, Goggins M. 2003. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res 63: 4158-4166.
59. Shackleton M, Quintana E, Fearon ER, Morrison SJ. 2009. Heterogeneity in cancer: Cancer stem cells versus clonal evolution. Cell 138: 822-829.
60. Somervaille TC, Matheny CJ, Spencer GJ, Iwasaki M, Rinn JL, Witten DM, Chang HY, Shurtleff SA, Downing JR, Cleary ML. 2009. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 4: 129-140.
61. Stoll G, Muller HW. 1999. Nerve injury, axonal degeneration and neural regeneration: Basic insights. Brain Pathol 9: 313-325.
62. Takahashi K, Yamanaka S. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676.
63. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872.
64. Ting AH, McGarvey KM, Baylin SB. 2006. The cancer epigenome: Components and functional correlates. Genes Dev 20: 3215-3231.
65. Ting AH, Suzuki H, Cope L, Schuebel KE, Lee BH, Toyota M, Imai K, Shinomura Y, Tokino T, Baylin SB. 2008. A requirement for DICER to maintain full promoter CpG island hypermethylation in human cancer cells. Cancer Res 68: 2570-2575.
66. Ugolkov AV, Eisengart LJ, Luan C, Yang XJ. 2010. Expression analysis of putative stem cell markers in human benign and malignant prostate. Prostate (in press).
67. Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RM, Khalil A, Rheinwald JG, Hochedlinger K. 2009. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 460: 1145-1148.
68. Varlakhanova NV, Knoepfler PS. 2009. Acting locally and globally: Myc's ever-expanding roles on chromatin. Cancer Res 69: 7487-7490.
69. Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, Li GM, Drummond J, Modrich PL, Sedwick WD, et al. 1998. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci 95: 8698-8702.
70. Visone R, Croce CM. 2009. MiRNAs and cancer. Am J Pathol 174: 1131-1138.
71. Viswanathan SR, Daley GQ. 2010. Lin28: A microRNA regulator with a macro role. Cell 140: 445-449.
72. Wade PA, Gegonne A, Jones PL, Ballestar E, Aubry F, Wolffe AP. 1999. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat Genet 23: 62-66.
73. Wang JC. 2010. Good cells gone bad: The cellular origins of cancer. Trends Mol Med 16: 145-151.
74. Weber B, Stresemann C, Brueckner B, Lyko F. 2007. Methylation of human microRNA genes in normal and neoplastic cells. Cell Cycle 6: 1001-1005.
75. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, Chang HY. 2008. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2: 333-344.
76. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, et al. 2007. Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917-1920.
77. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. 2009. Tumour-initiating cells: Challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 8: 806-823.
78. Zhu L, Gibson P, Currle DS, Tong Y, Richardson RJ, Bayazitov IT, Poppleton H, Zakharenko S, Ellison DW, Gilbertson RJ. 2009. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 457: 603-607.